Your browser is no longer supported. Please, upgrade your browser.
Settings
YMTX [NASD]
Yumanity Therapeutics, Inc.
Index- P/E- EPS (ttm)-21.57 Insider Own8.10% Shs Outstand10.19M Perf Week-11.59%
Market Cap149.33M Forward P/E- EPS next Y-6.42 Insider Trans0.00% Shs Float6.49M Perf Month-21.61%
Income-50.80M PEG- EPS next Q-0.83 Inst Own36.90% Short Float6.49% Perf Quarter-28.26%
Sales6.90M P/S21.64 EPS this Y6.70% Inst Trans-0.03% Short Ratio6.38 Perf Half Y-32.73%
Book/sh23.88 P/B0.62 EPS next Y-51.80% ROA-66.30% Target Price- Perf Year-51.63%
Cash/sh8.45 P/C1.75 EPS next 5Y- ROE-106.20% 52W Range14.48 - 39.00 Perf YTD-12.94%
Dividend- P/FCF- EPS past 5Y2.40% ROI-76.60% 52W High-62.05% Beta0.70
Dividend %- Quick Ratio2.80 Sales past 5Y9.80% Gross Margin- 52W Low2.21% ATR0.98
Employees44 Current Ratio2.80 Sales Q/Q- Oper. Margin- RSI (14)31.77 Volatility6.66% 5.58%
OptionableYes Debt/Eq0.29 EPS Q/Q-367.50% Profit Margin- Rel Volume0.58 Prev Close14.65
ShortableYes LT Debt/Eq0.24 Earnings- Payout- Avg Volume66.09K Price14.80
Recom1.50 SMA20-14.65% SMA50-17.21% SMA200-31.84% Volume38,164 Change1.02%
May-04-21 08:00AM  
Apr-28-21 08:07PM  
Apr-22-21 07:00AM  
Apr-13-21 08:00AM  
Apr-06-21 08:00AM  
Mar-31-21 08:48AM  
Mar-23-21 09:41AM  
Mar-09-21 08:00AM  
Mar-02-21 04:05PM  
Feb-10-21 08:00AM  
Jan-06-21 08:00AM  
Yumanity Therapeutics Inc., a clinical stage biopharmaceutical company, engages in the research and development of treatments for neurodegenerative diseases caused by protein misfolding. It focuses on discovering disease-modifying therapies to treat Parkinson's disease, dementia with Lewy bodies, multiple system atrophy, amyotrophic lateral sclerosis, frontotemporal lobar degeneration, and Alzheimer's diseases. Its lead program is YTX-7739, a novel small molecule for the treatment of Parkinson's disease and related disorders of a-synuclein that is in Phase I clinical trial. The company is also developing YTX-9184 for the treatment of dementia with Lewy bodies. Yumanity Therapeutics Inc. has a strategic research and development collaboration agreement with Merck Sharp & Dohme Corp. The company is headquartered in Boston, Massachusetts.